Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Jensen

Showing results (1-10 of 115) with videos related to

Pageof 12
Sort By:
Danish Medical Bulletin|November 1, 1994
Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugsP B Jensen
Scandinavian Journal of Psychology|January 1, 1987
Psychological aspects of myelomeningocele--a longitudinal studyP B Jensen
Lancet (London, England)|June 23, 1990
Effects of halting a cervical screening programmeP B Jensen, C Birch
Ugeskrift for Laeger|June 25, 1971
[Bovine leukosis, human leukemia and related diseases. An epidemiologic examination in a Danish island community 1957-62]E Henriksen, P B Jensen
Ugeskrift for Laeger|June 28, 1993
[Development of use of subsidized prescription drugs. A comparison of drug consumption requiring subsidy in the county of Storstrøm during the periods 1 January--30 April 1991 and 1 January--30 April 1992]P B Jensen, M Vass
Cancer Treatment and Research|January 1, 1995
In vitro models for testing of cytostatic agents in small cell lung cancerP B Jensen, M Sehested
Acta Neurologica Scandinavica|January 1, 1987
Evaluation of the urinary tract in children with myelomeningoceleT Petersen, P B Jensen
Biochemical Pharmacology|April 12, 1996
Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycleM Sehested, P B Jensen
Ugeskrift for Laeger|March 23, 1981
[Arsenic consumption as the cause of portal hypertension]P B Jensen, L Ranek
Biochemical Pharmacology|November 14, 1997
DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposideP B Jensen, M Sehested
Pageof 12

Showing results (1-10 of 115) with videos related to

Sort By:
Pageof 12
Danish Medical Bulletin|November 1, 1994
Differential sensitivity patterns in small cell lung cancer cell lines: detection and circumvention of resistance to topoisomerase II targeting drugsP B Jensen
Scandinavian Journal of Psychology|January 1, 1987
Psychological aspects of myelomeningocele--a longitudinal studyP B Jensen
Lancet (London, England)|June 23, 1990
Effects of halting a cervical screening programmeP B Jensen, C Birch
Ugeskrift for Laeger|June 25, 1971
[Bovine leukosis, human leukemia and related diseases. An epidemiologic examination in a Danish island community 1957-62]E Henriksen, P B Jensen
Ugeskrift for Laeger|June 28, 1993
[Development of use of subsidized prescription drugs. A comparison of drug consumption requiring subsidy in the county of Storstrøm during the periods 1 January--30 April 1991 and 1 January--30 April 1992]P B Jensen, M Vass
Cancer Treatment and Research|January 1, 1995
In vitro models for testing of cytostatic agents in small cell lung cancerP B Jensen, M Sehested
Acta Neurologica Scandinavica|January 1, 1987
Evaluation of the urinary tract in children with myelomeningoceleT Petersen, P B Jensen
Biochemical Pharmacology|April 12, 1996
Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycleM Sehested, P B Jensen
Ugeskrift for Laeger|March 23, 1981
[Arsenic consumption as the cause of portal hypertension]P B Jensen, L Ranek
Biochemical Pharmacology|November 14, 1997
DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposideP B Jensen, M Sehested
Pageof 12